Confirming that the effects of SAA positivity on accelerated tau accumulation were driven by subjects on the AD spectrum (i.e. Aβ+), we found that SAA positivity had a significant main effect on faster tau-PET change rates in the temporal meta-ROI in the Aβ+ (p = 0.037) but not in the Aβ- subjects (p = 0.899), controlling for age, sex, study site and centiloid levels. The gene discussed is MAPT; the disease is Alzheimer disease.